Detalle Publicación


Evolution of the cardiometabolic profile of primary hyperaldosteronism patients treated with adrenalectomy and with mineralocorticoid receptor antagonists: results from the SPAIN-ALDO Registry

Autores: Araujo-Castro, M. (Autor de correspondencia); Paja Fano, M.; González Boillos, M.; Pla Peris, B.; Pascual-Corrales, E.; García Cano, A. M.; Parra Ramírez, P.; Martín Rojas-Marcos, P.; Ruiz-Sánchez, J. G.; Vicente Delgado, A.; Gómez Hoyos, E.; Ferreira, R.; García Sanz, I.; Díaz Guardiola, P.; García González, J. J.; Perdomo Zelaya, Carolina María; Morales, M.; Hanzu, F. A.
Título de la revista: ENDOCRINE
ISSN: 1559-0100
Volumen: 76
Número: 3
Páginas: 687 - 696
Fecha de publicación: 2022
Objective To analyze the evolution of the cardiometabolic profile of patients with primary hyperaldosteronism (PA) after the treatment with surgery and with mineralocorticoid receptor antagonists (MRA). Design Retrospective multicentric study of patients with PA on follow-up in twelve Spanish centers between 2018 and 2020. Results 268 patients with PA treated by surgery (n = 100) or with MRA (n = 168) were included. At baseline, patients treated with surgery were more commonly women (54.6% vs 41.7%, P = 0.042), had a higher prevalence of hypokalemia (72.2% vs 58%, P = 0.022) and lower prevalence of obesity (37.4% vs 51.3%, P = 0.034) than patients treated with MRA. Adrenalectomy resulted in complete biochemical cure in 94.0% and clinical response in 83.0% (complete response in 41.0% and partial response in 42.0%). After a median follow-up of 23.6 (IQR 9.7-53.8) months, the reduction in blood pressure (BP) after treatment was similar between the group of surgery and MRA, but patients surgically treated reduced the number of antihypertensive pills for BP control more than those medically treated ( increment antihypertensives: -1.3 +/- 1.3 vs 0.0 +/- 1.4, P < 0.0001) and experienced a higher increased in serum potassium levels ( increment serum potassium: 0.9 +/- 0.7 vs 0.6 +/- 0.8mEq/ml, P = 0.003). However, no differences in the risk of the onset of new renal and cardiometabolic comorbidities was observed between the group of surgery and MRA (HR = 0.9 [0.5-1.5], P = 0.659). Conclusion In patients with PA, MRA and surgery offer a similar short-term cardiovascular protection, but surgery improves biochemical control and reduces pill burden more commonly than MRA, and lead to hypertension cure or improvement in up to 83% of the patients.